Splice variant v6 of CD44 (CD44v6); phosphoinositide 3-kinase (PI3K) BriefCommunication Pages: 396 - 396
Jagged 1 (JAG1); notch 2 (NOTCH2); fibroblast growth factor 4 (FGF4); fibroblast growth factor receptor 1 (FGFR1; CD331) BriefCommunication Pages: 397 - 397
Ubiquitin specific peptidase 1 (USP1); WD repeat domain 48 (WDR48; UAF1) BriefCommunication Pages: 398 - 398
Peroxisome proliferation–activated receptor-γ (PPARG; PPARγ); myeloid-lymphoma or mixed-lineage 5 (MLL5); 5′-3′ exoribonuclease 2 (XRN2) BriefCommunication Pages: 400 - 400
Nanoparticles for in vivo detection of drug-induced hepatotoxicity BriefCommunication Pages: 408 - 408
Polymerized antibody–tagged magnetic beads for isolation of circulating tumor cells (CTCs) BriefCommunication Pages: 409 - 409
Protein misfolding cyclic amplification (PMCA) technique to create α-synuclein (SNCA) aggregates for drug screening BriefCommunication Pages: 410 - 410
Mouse model of amyotrophic lateral sclerosis (ALS) caused by partial loss of TAR DNA binding protein 43 (Tdp-43; Tardbp) function BriefCommunication Pages: 412 - 412
Pituitary ablation of estrogen receptor expression as a mouse model for ovarian cancer BriefCommunication Pages: 413 - 413
Carbonic anhydrase IX (CAIX)-targeted small molecule–drug conjugates BriefCommunication Pages: 414 - 414
Crystal structure of purinergic receptor P2Y G protein–coupled 12 (P2RY12; P2Y12) bound to an antagonist BriefCommunication Pages: 415 - 415
Enhanced antigen-specific T cell activation using nanoscale artificial antigen-presenting cells (aAPCs) in a magnetic field BriefCommunication Pages: 416 - 416